Farms.com Home   News

FIRST soybean tests show strong yields

Yield reports are in from fields across the Midwest and impacts of the ongoing drought are proving to be less than expected.

This year’s Farmers’ Independent Research of Seed Technologies (FIRST) soybean yield results showed strong production overall despite some tough conditions.

Iowa saw wide variability in soybean yields across the state. In the northernmost sites, yields ranged from 37.6 bushels per acre in Iowa Falls to 67.7 in Hull. The 37.6 bu./acre figure was an outlier, with only one of the other six sites, Osage, posting a sub-50 average yield.

The variability is illustrated comparing Iowa Falls’ low yield to nearby Ventura, which averaged 63.4 bushels per acre. Both those sites are in the north central region, roughly 56 miles from each other.

In the southern portion of Iowa, yields were exceptional. In the FIRST sites managed by Randy Meinsma, yields ranged from 60.7 in Central City to 80.3 in Washington. Cambria, in south central Iowa, posted an average 72.3 bu./acre, while the westernmost site in Oakland reached an average of 70.1.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.